相关临床试验
193
21 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1821
进行中（未招募）
11
5.7%
已完成
118
61.1%
Enrolling By Invitation
2
1.0%
尚未招募
8
4.2%
招募中
28
14.5%
终止
15
7.8%
Unknown
1
0.5%
撤回
10
5.2%
暂无批准数据
- Researchers from George Washington University and Baylor College of Medicine report promising results from a phase 2 trial of an investigational hookworm vaccine, showing dramatically reduced infection intensity in healthy volunteers. - The Na-GST-1/Al-CpG vaccine formulation reduced median hookworm egg counts to 0.0 eggs per gram of feces compared to 66.7 eggs in the placebo group during controlled human infection studies. - Hookworm affects an estimated 113-400 million people globally and is a major cause of iron-deficiency anemia, particularly impacting children and pregnant women in low-resource settings. - The successful vaccine candidate will advance to further clinical evaluation as either a standalone treatment or potentially as part of a combination vaccine targeting multiple parasitic diseases.
- An FDA expert panel convened to reassess boxed warnings for menopausal hormone therapy, with multiple experts arguing that current labels overstate risks and are not supported by comprehensive scientific evidence. - Panel members presented data showing that vaginal estrogen products carry significantly different safety profiles than systemic hormone therapy, yet both carry identical boxed warnings due to class labeling regulations. - Experts highlighted critical gaps in medical education, noting that only 31.3% of U.S. residency programs have standardized menopause training, contributing to underutilization of beneficial therapies. - The panel emphasized that reanalysis of Women's Health Initiative data shows favorable outcomes for women aged 50-59 years, with estrogen alone linked to reduced breast cancer incidence and mortality over long-term follow-up.
- Nanochon has received Health Canada approval for a first-in-human clinical trial of its 3D printed Chondrograft implant to treat articular cartilage defects in the knee. - The prospective, 10-patient early feasibility study will evaluate the safety and performance of the minimally-invasive implant in patients aged 22-60 with failed conservative therapy. - The trial aims to assess cartilage-bone matrix regrowth, improved knee function and pain reduction, and delayed need for arthroplasty in patients with femoral condyle and trochlea lesions. - This represents the first step toward a larger North American clinical program for addressing the unmet need in thousands of patients with chondral defects.
- Breathe BioMedical launches multi-center clinical trial at George Washington University Breast Center to develop a breath-based detection test for breast cancer in women with dense breast tissue. - The study, led by Mayo Clinic experts, aims to identify disease-specific breath patterns by comparing profiles between women with and without breast cancer, addressing the limitations of traditional mammography. - The technology targets a significant medical need, as 50% of U.S. screening-eligible women have dense breast tissue, where mammography sensitivity can drop to as low as 40%.
• A case study reports a 57% reduction in tumor volume in a metastatic prostate cancer patient treated with trastuzumab deruxtecan (T-DXd). • The patient, who had stage four metastatic prostate cancer and failed multiple lines of therapy, showed significant improvement after T-DXd treatment. • The study highlights the potential of T-DXd in aggressive prostate cancer and the importance of HER2 expression testing. • This is the first known case of using T-DXd for prostate cancer treatment, offering a potential new therapeutic avenue.
- A groundbreaking HIV vaccine using "germline targeting" successfully generated antibodies in 97% of participants in a Phase 1 trial, with no severe side effects reported. - The innovative approach aims to stimulate rare immune cells to produce broadly neutralizing antibodies that can protect against multiple HIV variants, addressing the virus's rapid mutation challenge. - Researchers from George Washington University, Scripps Research, and partners developed a customized immunogen that "primes" the immune system, potentially opening new pathways for vaccines against other fast-mutating viruses.
